The need for sustaining mpox vaccination in Africa Authors: Yap Boum, Reena H. Doshi, Charles U. Ibeneme, Sheillah Nsasiirwe, Nebiyu Dereje, Hilary Njenge, Alba Vilajeliu, Thierno Balde, Ngashi Ngongo, Jean Kaseya, Rosamund F. Lewis Published: 2026 ABSTRACT Sustaining and transitioning mpox vaccination requires establishing and resourcing a global mpox vaccine stockpile under the Inter-Agency Coordinating Group (ICG), supported by sustainable financing, transparent allocation criteria, diversified manufacturing (including local production in Africa), and robust logistics, surveillance, and operational systems. Moreover, it requires strengthened collaboration among global, regional, and community actors; continuous data generation and research to inform policy, including genomic and vaccine effectiveness studies; and accelerated R&D with fast-tracked local manufacturing to enhance supply resilience and long-term epidemic preparedness. Ensuring sustainable access to affordable vaccines for epidemic-prone infectious disease outbreaks in Africa remains a challenge. In the case of mpox, vaccination with available vaccines against orthopoxvirus diseases was demonstrated to be effective during the global mpox epidemic, which began in 20221. To secure equitable access for Africa during a surging multi-country outbreak of mpox in 2024, public health agencies partnered to coordinate the supply and allocation of mpox vaccines to countries2–4. WHO prequalification of MVA-BN for mpox in September 2024—initially for adults, later expanded to those aged ≥12 years, at USD 65–130 per dose—enabled large-scale resource mobilization through coordinated procurement and donations2. In parallel, Japan committed to donate over 3 million doses of LC16m8 to the Democratic Republic of the Congo (DRC), a vaccine subsequently listed by WHO for emergency use in November 20243. Since August 2024, 16 African countries have received over five million doses and vaccinated approximately two million people, despite waning global attention, including an undelivered US pledged vaccine donation3. With public health emergency declarations lifted by the WHO and the Africa CDC, attention turns to the next phase for mpox vaccination in Africa, including strategies to interrupt transmission, protect the vulnerable populations, such as pregnant women and children, prevent outbreaks in populations at risk, and progress towards the elimination of mpox as a public health problem5. Transitioning mpox control from emergency response to existing health programmes requires policies that reduce the risk of future outbreaks, sustain capacity for rapid response, and introduce preventive strategies5,6. Effective transition planning is essential to sustain engagement across relevant programmes, including surveillance, maternal and child health, HIV/STI services, and immunization programmes as needed. This must be paired with support to national regulatory authorities and pooled procurement to reduce costs, strengthen bargaining power, and guarantee access for Africa, alongside sustained access to diagnostics and other poxvirus preparedness tools. The trajectory of mpox control in Africa may mirror that of meningococcal disease and yellow fever, which offer important lessons for managing epidemic-prone diseases7,8. Effective long-term prevention will depend on a strong understanding of epidemiology, robust global and regional coordination, and the strategic combination of preventive vaccination with reactive vaccination during outbreaks. For meningococcal disease and yellow fever, hybrid approaches, routine immunization complemented by periodic preventive campaigns in endemic areas, have been key to achieving high population immunity. Applied to mpox, routine or catch-up vaccination in selected endemic settings, combined with targeted prevention and response in non-endemic areas, offers a pragmatic and sustainable path forward. These strategies must be supported by strong community engagement and behavior-change interventions to reduce transmission. For both meningococcal disease and yellow fever, a global vaccine reserve managed by the International Coordinating Group (ICG) on Vaccine Provision ensures equitable and timely access to vaccines during outbreaks8–10. Expected to become operational for mpox by mid-2026, the ICG model will enable rapid emergency deployment of mpox vaccines, building on mechanisms already used for meningococcal disease, yellow fever, cholera, and Ebola virus disease. Close coordination between the ICG, partners such as Gavi, the vaccine alliance, and regional institutions such as the Africa CDC will be critical to strengthen operational delivery in Africa, where the burden is highest. Broadening access to other vaccines, such as LC16m8, and encouraging use of vaccine dose-sparing strategies (single-dose schedules and intradermal fractional dosing) for MVA-BN, could further expand access by reducing unit costs and extending limited supplies. Similar approaches have successfully increased coverage during yellow fever outbreaks and polio eradication efforts, alongside other interventions such as OPV campaigns and strengthened surveillance systems11–13. Mpox control must also draw lessons from HIV and other sexually transmitted infections, emphasizing vulnerable populations, community partnership, and the reduction of stigma and discrimination. Africa can leverage its long experience in epidemic control to build a sustainable and equitable mpox vaccination model, through closing evidence gaps, adapting vaccine platforms, and strengthening regional leadership. Despite the MVA-BN and LC16m8 vaccine effectiveness and safety studies (clinical trials) being conducted in DRC, critical data are still needed on disease transmission, vaccine effectiveness, duration of protection, cost-effectiveness, and community engagement to guide primary preventive vaccination and inform global policy-setting, while increased vaccine demand can catalyze local manufacturing, strengthening Africa’s health security and sovereignty. Strengthening surveillance could also provide data on disease patterns and immunological status. Close monitoring of emerging vaccine platforms, including mRNA and other mpox vaccines, is essential to ensure sustainable and affordable access. mRNA mpox vaccines’ local production capacity will require accelerated technology transfer and licensing agreements, sustainable financing mechanisms, regulatory harmonization through the African Medicines Agency, investment in biomanufacturing workforce and infrastructure, strengthened genomic surveillance and clinical research capacity, and development of resilient regional supply chains14. Beyond improving equitable access to mpox vaccines during outbreaks, local mRNA manufacturing can establish a scalable platform for responding to future epidemic and pandemic threats across Africa. Key actions to ensure the sustainability of mpox vaccination Recognizing that control of mpox in endemic areas is now central to global health security, successful advancement of preventive mpox vaccination strategies globally and in Africa will depend as much on governance and coordination as on science. The following key actions are needed:Establish and appropriately resource the ICG global mpox vaccine stockpile to secure rapid and equitable access to vaccines for outbreak response. This include: (i) securing sustainable financing commitments from donors, multilateral agencies, and regional financing mechanisms to procure and maintain adequate vaccine reserves; (ii) defining transparent allocation and deployment criteria based on epidemiological risk, outbreak severity, and equity considerations; (iii) supporting advance purchase agreements and diversified manufacturing partnerships, including regional production capacity in Africa, to ensure reliable supply; (iv) strengthening cold-chain, warehousing, and last-mile delivery systems to enable rapid deployment to affected countries; (v) developing standardized operational guidelines for stockpile activation, regulatory approvals, and cross-border distribution during emergencies; (vi) establishing real-time surveillance, forecasting, and stock management systems to monitor vaccine demand, utilization, and replenishment needs; and (vii) conducting regular simulation exercises and after-action reviews to assess readiness and improve coordination among the ICG, national governments, regional bodies.Enhance collaboration across global and regional agencies and community organizations to provide technical, operational and financial support to countries and communities. Specific activities include establishing coordinated platforms among global, regional, and community actors; providing joint technical assistance for surveillance, vaccine deployment, risk communication, and outbreak response; strengthening data-sharing, laboratory, logistics, and rapid response systems; supporting community-led engagement to address misinformation and improve vaccine uptake; and mobilizing rapid financing through mechanisms such as the Africa Epidemic Fund to accelerate vaccine procurement and emergency response.Continue generation of data to advance understanding of mpox virus epidemiology, including evolving variants of the mpox virus and vaccine longevity among various groups of the population to support policy for prevention and response, and integrate effective strategies. Specific activities include strengthening genomic surveillance to monitor emerging mpox variants and transmission dynamics; expanding epidemiological and operational research on vaccine effectiveness, duration of protection, and breakthrough infections across different population groups; improving data systems for real-time case reporting and analysis; supporting multicountry studies and data-sharing platforms; and generating evidence on effective prevention, vaccination, and community engagement strategies to inform national, regional, and global policy and response frameworks.Accelerate research and development for vaccines and fast-track local manufacturing where feasible to improve supply and local resilience. Specific activities include increasing investment in research and clinical trials for improved next-generation vaccines for mpox; strengthening regulatory pathways and ethical review systems to accelerate approval and deployment of new tools; supporting technology transfer, workforce development, and regional manufacturing partnerships to expand local production capacity; enhancing laboratory and quality assurance systems to ensure safe and effective products; and promoting coordinated procurement and market-shaping mechanisms to improve equitable access and long-term health security resilience. Establish and appropriately resource the ICG global mpox vaccine stockpile to secure rapid and equitable access to vaccines for outbreak response. This include: (i) securing sustainable financing commitments from donors, multilateral agencies, and regional financing mechanisms to procure and maintain adequate vaccine reserves; (ii) defining transparent allocation and deployment criteria based on epidemiological risk, outbreak severity, and equity considerations; (iii) supporting advance purchase agreements and diversified manufacturing partnerships, including regional production capacity in Africa, to ensure reliable supply; (iv) strengthening cold-chain, warehousing, and last-mile delivery systems to enable rapid deployment to affected countries; (v) developing standardized operational guidelines for stockpile activation, regulatory approvals, and cross-border distribution during emergencies; (vi) establishing real-time surveillance, forecasting, and stock management systems to monitor vaccine demand, utilization, and replenishment needs; and (vii) conducting regular simulation exercises and after-action reviews to assess readiness and improve coordination among the ICG, national governments, regional bodies. Establish and appropriately resource the ICG global mpox vaccine stockpile to secure rapid and equitable access to vaccines for outbreak response. This include: (i) securing sustainable financing commitments from donors, multilateral agencies, and regional financing mechanisms to procure and maintain adequate vaccine reserves; (ii) defining transparent allocation and deployment criteria based on epidemiological risk, outbreak severity, and equity considerations; (iii) supporting advance purchase agreements and diversified manufacturing partnerships, including regional production capacity in Africa, to ensure reliable supply; (iv) strengthening cold-chain, warehousing, and last-mile delivery systems to enable rapid deployment to affected countries; (v) developing standardized operational guidelines for stockpile activation, regulatory approvals, and cross-border distribution during emergencies; (vi) establishing real-time surveillance, forecasting, and stock management systems to monitor vaccine demand, utilization, and replenishment needs; and (vii) conducting regular simulation exercises and after-action reviews to assess readiness and improve coordination among the ICG, national governments, regional bodies. Enhance collaboration across global and regional agencies and community organizations to provide technical, operational and financial support to countries and communities. Specific activities include establishing coordinated platforms among global, regional, and community actors; providing joint technical assistance for surveillance, vaccine deployment, risk communication, and outbreak response; strengthening data-sharing, laboratory, logistics, and rapid response systems; supporting community-led engagement to address misinformation and improve vaccine uptake; and mobilizing rapid financing through mechanisms such as the Africa Epidemic Fund to accelerate vaccine procurement and emergency response. Enhance collaboration across global and regional agencies and community organizations to provide technical, operational and financial support to countries and communities. Specific activities include establishing coordinated platforms among global, regional, and community actors; providing joint technical assistance for surveillance, vaccine deployment, risk communication, and outbreak response; strengthening data-sharing, laboratory, logistics, and rapid response systems; supporting community-led engagement to address misinformation and improve vaccine uptake; and mobilizing rapid financing through mechanisms such as the Africa Epidemic Fund to accelerate vaccine procurement and emergency response. Continue generation of data to advance understanding of mpox virus epidemiology, including evolving variants of the mpox virus and vaccine longevity among various groups of the population to support policy for prevention and response, and integrate effective strategies. Specific activities include strengthening genomic surveillance to monitor emerging mpox variants and transmission dynamics; expanding epidemiological and operational research on vaccine effectiveness, duration of protection, and breakthrough infections across different population groups; improving data systems for real-time case reporting and analysis; supporting multicountry studies and data-sharing platforms; and generating evidence on effective prevention, vaccination, and community engagement strategies to inform national, regional, and global policy and response frameworks. Continue generation of data to advance understanding of mpox virus epidemiology, including evolving variants of the mpox virus and vaccine longevity among various groups of the population to support policy for prevention and response, and integrate effective strategies. Specific activities include strengthening genomic surveillance to monitor emerging mpox variants and transmission dynamics; expanding epidemiological and operational research on vaccine effectiveness, duration of protection, and breakthrough infections across different population groups; improving data systems for real-time case reporting and analysis; supporting multicountry studies and data-sharing platforms; and generating evidence on effective prevention, vaccination, and community engagement strategies to inform national, regional, and global policy and response frameworks. Accelerate research and development for vaccines and fast-track local manufacturing where feasible to improve supply and local resilience. Specific activities include increasing investment in research and clinical trials for improved next-generation vaccines for mpox; strengthening regulatory pathways and ethical review systems to accelerate approval and deployment of new tools; supporting technology transfer, workforce development, and regional manufacturing partnerships to expand local production capacity; enhancing laboratory and quality assurance systems to ensure safe and effective products; and promoting coordinated procurement and market-shaping mechanisms to improve equitable access and long-term health security resilience. Accelerate research and development for vaccines and fast-track local manufacturing where feasible to improve supply and local resilience. Specific activities include increasing investment in research and clinical trials for improved next-generation vaccines for mpox; strengthening regulatory pathways and ethical review systems to accelerate approval and deployment of new tools; supporting technology transfer, workforce development, and regional manufacturing partnerships to expand local production capacity; enhancing laboratory and quality assurance systems to ensure safe and effective products; and promoting coordinated procurement and market-shaping mechanisms to improve equitable access and long-term health security resilience. Global and regional mpox epidemics have exposed a widening orthopoxvirus immunity gap and underscored the need for better, more sustainable preparedness1. Global vaccine supply remains tightly linked to country demand, which, in turn, is limited by high prices and by restrictive immunization policies. Preventive pre-exposure vaccination strategies, adapted to diverse epidemiological and programmatic contexts, are essential to translating lessons learned into durable immunity where it is most needed and global health security. This will require African leadership, sustained global solidarity, and equitable, long-term access to diagnostics and vaccines to track, respond to, and stay ahead of mpox as a global health issue.